KALEIDO BIOSCIENCES INC (KLDO) Fundamental Analysis & Valuation

NASDAQ:KLDO • US4833471000

Current stock price

0.29
-0.01 (-3.69%)
At close:
0.3003
+0.01 (+3.55%)
After Hours:

This KLDO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. KLDO Profitability Analysis

1.1 Basic Checks

  • In the past year KLDO has reported negative net income.
KLDO Yearly Net Income VS EBIT VS OCF VS FCFKLDO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -180.08%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KLDO Yearly ROA, ROE, ROICKLDO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 500 -500

1.3 Margins

  • The Operating Margin and Gross Margin are not available for KLDO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -8155.92%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KLDO Yearly Profit, Operating, Gross MarginsKLDO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. KLDO Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, KLDO has more shares outstanding
  • Compared to 1 year ago, KLDO has a worse debt to assets ratio.
KLDO Yearly Shares OutstandingKLDO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
KLDO Yearly Total Debt VS Total AssetsKLDO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -15.43, we must say that KLDO is in the distress zone and has some risk of bankruptcy.
  • A Debt/Equity ratio of 0.52 indicates that KLDO is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z -15.43
ROIC/WACCN/A
WACCN/A
KLDO Yearly LT Debt VS Equity VS FCFKLDO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M -60M

2.3 Liquidity

  • KLDO has a Current Ratio of 1.43. This is a normal value and indicates that KLDO is financially healthy and should not expect problems in meeting its short term obligations.
  • KLDO has a Quick Ratio of 1.43. This is a normal value and indicates that KLDO is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.43
KLDO Yearly Current Assets VS Current LiabilitesKLDO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. KLDO Growth Analysis

3.1 Past

  • KLDO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.65%, which is quite good.
  • KLDO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.12%.
EPS 1Y (TTM)11.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.48%
Revenue 1Y (TTM)14.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%105%

3.2 Future

  • Based on estimates for the next years, KLDO will show a small growth in Earnings Per Share. The EPS will grow by 0.99% on average per year.
  • The Revenue is expected to grow by 252.50% on average over the next years. This is a very strong growth
EPS Next Y10.24%
EPS Next 2Y9.33%
EPS Next 3Y4.15%
EPS Next 5Y0.99%
Revenue Next Year-36.87%
Revenue Next 2Y401.97%
Revenue Next 3Y295.27%
Revenue Next 5Y252.5%

3.3 Evolution

KLDO Yearly Revenue VS EstimatesKLDO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
KLDO Yearly EPS VS EstimatesKLDO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. KLDO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KLDO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KLDO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KLDO Price Earnings VS Forward Price EarningsKLDO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.05
KLDO Per share dataKLDO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.33%
EPS Next 3Y4.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KLDO Dividend Analysis

5.1 Amount

  • No dividends for KLDO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

KLDO Fundamentals: All Metrics, Ratios and Statistics

KALEIDO BIOSCIENCES INC

NASDAQ:KLDO (4/14/2022, 8:00:02 PM)

After market: 0.3003 +0.01 (+3.55%)

0.29

-0.01 (-3.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-01
Earnings (Next)05-02
Inst Owners0.01%
Inst Owner Change3685.71%
Ins Owners4.76%
Ins Owner Change0%
Market Cap12.36M
Revenue(TTM)1.11M
Net Income(TTM)-90.29M
Analysts76.67
Price Target11.91 (4006.9%)
Short Float %0.17%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.17
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB N/A
EV/EBITDA 0.05
EPS(TTM)-2.16
EYN/A
EPS(NY)-2.07
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.03
BVpS0.25
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -180.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -8155.92%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 1.43
Altman-Z -15.43
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.48%
EPS Next Y10.24%
EPS Next 2Y9.33%
EPS Next 3Y4.15%
EPS Next 5Y0.99%
Revenue 1Y (TTM)14.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%105%
Revenue Next Year-36.87%
Revenue Next 2Y401.97%
Revenue Next 3Y295.27%
Revenue Next 5Y252.5%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

KALEIDO BIOSCIENCES INC / KLDO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KALEIDO BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to KLDO.


What is the valuation status of KALEIDO BIOSCIENCES INC (KLDO) stock?

ChartMill assigns a valuation rating of 3 / 10 to KALEIDO BIOSCIENCES INC (KLDO). This can be considered as Overvalued.


What is the profitability of KLDO stock?

KALEIDO BIOSCIENCES INC (KLDO) has a profitability rating of 1 / 10.